Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients

References

• Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.
   PubMed Web of Science ®Google Scholar
• Coronavirus disease (COVID-19) situation reports [Internet]. [cited 2021 Feb 24]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
   Google Scholar
• Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801–2809.
   PubMed Web of Science ®Google Scholar
• Longhitano Y, Racca F, Zanza C, et al. Venous thromboembolism in critically ill patients affected by ARDS related to COVID-19 in Northern-West Italy. Eur Rev Med Pharmacol Sci. 2020;24:9154–9160.
   PubMed Web of Science ®Google Scholar
• Scudiero F, Silverio A, Di Maio M, et al. Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res. 2021;198:34–39.
   PubMed Web of Science ®Google Scholar
• Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488–1494.
   PubMed Web of Science ®Google Scholar
• Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158(3):1143–1163.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543–603.
   PubMed Web of Science ®Google Scholar
• Lewis P, Tharp JL. Breakthrough venous thromboembolic events in five patients with COVID‐19 on direct oral anticoagulants. J Clin Pharm Ther. 2021;46(2):519–523.
   PubMed Web of Science ®Google Scholar
• Ranieri VM, Rubenfeld GD, Thompson BT et al. ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307:2526–2533.
   PubMed Web of Science ®Google Scholar
• Stein PD, Yaekoub AY, Matta F, et al. Resolution of pulmonary embolism on CT pulmonary angiography. Am J Roentgenol. 2010;194(5):1263–1268.
   PubMed Web of Science ®Google Scholar
• Miesbach W. Pathological role of angiotensin II in severe COVID-19. TH Open. 2020;4(2):e138–e144.
   PubMedGoogle Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 2018;16(2):231–241.
   PubMed Web of Science ®Google Scholar
• Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost. 2019;17(2):283–294.
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950–2973.
   PubMed Web of Science ®Google Scholar
• Desai R, Gandhi Z, Singh S, et al. Prevalence of pulmonary embolism in COVID-19: a pooled analysis. SN Compr Clin Med. 2020;2(12):2722–2725.
   Google Scholar
• Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
   PubMed Web of Science ®Google Scholar
• CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098.
   PubMed Web of Science ®Google Scholar
• Di Micco P, Russo V, Carannante N, et al. Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian Cohort. JCM. 2020;9(5):1371.
   Web of Science ®Google Scholar
• Russo V, Cardillo G, Viggiano GV, et al. Fondaparinux use in patients with COVID-19: a preliminary multicenter real-world experience. J Cardiovasc Pharmacol. 2020;76(4):369–371.
   PubMed Web of Science ®Google Scholar
• Russo V, Cardillo G, Viggiano GV, et al. Thromboprofilaxys with Fondaparinux vs. Enoxaparin in hospitalized COVID-19 patients: a multicenter Italian observational study. Front Med. 2020;7:569567.
   PubMed Web of Science ®Google Scholar
• Arnold K, Xu Y, Sparkenbaugh EM, et al. Design of anti-inflammatory heparan sulfate to protect against acetaminophen-induced acute liver failure. Sci Transl Med. 2020;12(535):eaav8075.
   PubMed Web of Science ®Google Scholar
• Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117(3):437–444.
   PubMed Web of Science ®Google Scholar
• Russo V, Bottino R, Carbone A, et al. COVID-19 and heart: from clinical features to pharmacological implications. JCM. 2020;9(6):1944.
   Google Scholar
• Di Tano G, Moschini L, Loffi M, et al. Late pulmonary embolism after COVID-19 pneumonia despite adequate Rivaroxaban treatment. Eur J Case Rep Intern Med. 2020;7:001790.
   PubMedGoogle Scholar
• Cardillo G, Viggiano GV, Russo V, et al. Antithrombotic and anti-inflammatory effects of Fondaparinux and Enoxaparin in hospitalized COVID-19 patients: the Fondenoxavid study. JBM. 2021;12:69–75.
   Google Scholar
• Russo V, Proietti R, Lodigiani C, et al. Fondaparinux and bleeding risk in COVID-19: unsolved question. Thromb Res. 2021;200:128–129.
   PubMed Web of Science ®Google Scholar
• Corsini A, Ferri N, Proietti M, et al. Edoxaban and the issue of drug-drug interactions: from pharmacology to clinical practice. Drugs. 2020;80(11):1065–1083.
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Truitt KE. Pharmacokinetics and Pharmacodynamics of Edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55(6):641–655.
   PubMed Web of Science ®Google Scholar
• The Hokusai-VTE Investigators. Edoxaban versus Warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415.
   PubMed Web of Science ®Google Scholar
• Bottino R, Carbone A, Liccardo B, et al. Edoxaban (LIXIANA ®) in the treatment of venous thromboembolism. Future Cardiol. 2020 [Nov 24]. DOI: https://doi.org/10.2217/fca-2020-0139.
   Google Scholar
• Brekelmans MPA, Ageno W, Beenen LF, et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016;3(9):e437–e445.
   PubMed Web of Science ®Google Scholar
• Di Micco P, Russo V, Lodigiani C. Venous Thromboembolism and its association with COVID-19: still an open debate. Medicina (Kaunas). 2020;56(10):506.
   Web of Science ®Google Scholar